Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- nd RIG-1 agonist in patients with advanced solid tumors - Terheyden, P.; Weishaupt, C.; Heinzerling, Lucie; Klinkhardt, U.; Krauss, J.; Mohr, P.; Kiecker, F.; Becker, J. C.; Submitter, A. Daehling; Doener, F.; Heidenreich, R.; Scheel, B.; et al. (ANNALS OF ONCOLOGY, 2018)
CRIS-Team WoS Importer:2019-03-08